Idexx Laboratories [IDXX] vs Iqvia Holdings [IQV] Detailed Stock Comparison
Idexx Laboratories
NASDAQ
Loading...
Iqvia Holdings
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Idexx Laboratories wins in 10 metrics, Iqvia Holdings wins in 9 metrics, with 0 ties. Idexx Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Idexx Laboratories | Iqvia Holdings | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 54.06 | 27.69 | Iqvia Holdings |
| Price-to-Book Ratio | 35.76 | 5.62 | Iqvia Holdings |
| Debt-to-Equity Ratio | 84.81 | 272.12 | Idexx Laboratories |
| PEG Ratio | 1.11 | -1.25 | Iqvia Holdings |
| EV/EBITDA | 38.16 | 15.75 | Iqvia Holdings |
| Profit Margin (TTM) | 24.41% | 7.88% | Idexx Laboratories |
| Operating Margin (TTM) | 33.62% | 13.39% | Idexx Laboratories |
| EBITDA Margin (TTM) | 33.62% | 13.39% | Idexx Laboratories |
| Return on Equity | 64.87% | 19.79% | Idexx Laboratories |
| Return on Assets (TTM) | 23.26% | 5.16% | Idexx Laboratories |
| Free Cash Flow (TTM) | $798.08M | $2.11B | Iqvia Holdings |
| 1-Year Return | 32.21% | -20.26% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 12.90 | 2.07 | Iqvia Holdings |
| Enterprise Value | $53.14B | $46.05B | Idexx Laboratories |
| EV/Revenue Ratio | 13.16 | 2.93 | Iqvia Holdings |
| Gross Profit Margin (TTM) | 62.62% | 32.94% | Idexx Laboratories |
| Revenue per Share (TTM) | $50 | $89 | Iqvia Holdings |
| Earnings per Share (Diluted) | $12.04 | $6.90 | Idexx Laboratories |
| Beta (Stock Volatility) | 1.50 | 1.30 | Iqvia Holdings |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Idexx Laboratories vs Iqvia Holdings Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Idexx Laboratories | -0.48% | -1.10% | 23.58% | 27.12% | 44.93% | 59.19% |
| Iqvia Holdings | 0.89% | 6.24% | 21.19% | 36.07% | -1.07% | -2.07% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Idexx Laboratories | 32.21% | 74.14% | 69.73% | 777.14% | 2,182.05% | 4,061.38% |
| Iqvia Holdings | -20.26% | -20.05% | 21.27% | 161.98% | 350.79% | 350.79% |
Performance & Financial Health Analysis: Idexx Laboratories vs Iqvia Holdings
| Metric | IDXX | IQV |
|---|---|---|
| Market Information | ||
| Market Cap | $52.07B | $32.49B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 983,296 | 1,321,850 |
| 90 Day Avg. Volume | 698,835 | 2,042,897 |
| Last Close | $650.84 | $191.09 |
| 52 Week Range | $356.14 - $688.12 | $134.65 - $252.88 |
| % from 52W High | -5.42% | -24.43% |
| All-Time High | $706.95 (Jul 26, 2021) | $285.61 (Dec 27, 2021) |
| % from All-Time High | -7.94% | -33.09% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.05% |
| Quarterly Earnings Growth | 0.45% | -0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.24% | 0.08% |
| Operating Margin (TTM) | 0.34% | 0.13% |
| Return on Equity (TTM) | 0.65% | 0.20% |
| Debt to Equity (MRQ) | 84.81 | 272.12 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $18.20 | $33.99 |
| Cash per Share (MRQ) | $2.06 | $12.87 |
| Operating Cash Flow (TTM) | $905.81M | $2.62B |
| Levered Free Cash Flow (TTM) | $625.74M | $2.45B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Idexx Laboratories vs Iqvia Holdings
| Metric | IDXX | IQV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 54.06 | 27.69 |
| Forward P/E | 54.42 | 15.83 |
| PEG Ratio | 1.11 | -1.25 |
| Price to Sales (TTM) | 12.90 | 2.07 |
| Price to Book (MRQ) | 35.76 | 5.62 |
| Market Capitalization | ||
| Market Capitalization | $52.07B | $32.49B |
| Enterprise Value | $53.14B | $46.05B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 13.16 | 2.93 |
| Enterprise to EBITDA | 38.16 | 15.75 |
| Risk & Other Metrics | ||
| Beta | 1.50 | 1.30 |
| Book Value per Share (MRQ) | $18.20 | $33.99 |
Financial Statements Comparison: Idexx Laboratories vs Iqvia Holdings
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IDXX | IQV |
|---|---|---|
| Revenue/Sales | $998.43M | $3.83B |
| Cost of Goods Sold | $375.05M | $2.53B |
| Gross Profit | $623.38M | $1.30B |
| Research & Development | $59.06M | N/A |
| Operating Income (EBIT) | $316.53M | $525.00M |
| EBITDA | $351.81M | $786.00M |
| Pre-Tax Income | $310.08M | $323.00M |
| Income Tax | $67.41M | $61.00M |
| Net Income (Profit) | $242.68M | $249.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IDXX | IQV |
|---|---|---|
| Cash & Equivalents | $163.97M | $1.74B |
| Total Current Assets | $1.32B | $5.91B |
| Total Current Liabilities | $1.14B | $7.18B |
| Long-Term Debt | $546.80M | $13.29B |
| Total Shareholders Equity | $1.45B | $5.99B |
| Retained Earnings | $5.58B | $6.31B |
| Property, Plant & Equipment | $833.62M | $768.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IDXX | IQV |
|---|---|---|
| Operating Cash Flow | $235.07M | $554.00M |
| Capital Expenditures | $-30.03M | $-142.00M |
| Free Cash Flow | $207.94M | $426.00M |
| Debt Repayment | N/A | $-2.10B |
| Common Stock Repurchase | $-400.89M | $-375.00M |
Short Interest & Institutional Ownership Analysis
| Metric | IDXX | IQV |
|---|---|---|
| Shares Short | 2.48M | 6.80M |
| Short Ratio | 4.68 | 2.96 |
| Short % of Float | 0.04% | 0.05% |
| Average Daily Volume (10 Day) | 983,296 | 1,321,850 |
| Average Daily Volume (90 Day) | 698,835 | 2,042,897 |
| Shares Outstanding | 81.60M | 176.10M |
| Float Shares | 79.13M | 161.43M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.98% | 1.02% |
Dividend Analysis & Yield Comparison: Idexx Laboratories vs Iqvia Holdings
| Metric | IDXX | IQV |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |